Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs

Cheng, Qinglu; Cunningham, Evan B.; Shih, Sophy; Amin, Janaki; Bruneau, Julie; Artenie, Adelina A.; Powis, Jeff; Litwin, Alain H.; Cooper, Curtis; Dalgard, Olav; Hellard, Margaret; Bruggmann, Philip; Marks, Philippa; Lacombe, Karine; Stedman, Catherine; Read, Phillip; Hajarizadeh, Behzad; Dunlop, Adrian J.; Conway, Brian; Feld, Jordan J.; Dore, Gregory J.; Grebely, Jason; Grebely, Jason; Dore, Gregory; Marks, Philippa; Dalgard, Olav; Bruggmann, Philip; Stedman, Catherine; Lacombe, Karine; Powis, Jeff; Hellard, Margaret; Crawford, Sione; Swan, Tracy; Byrne, Jude; Coordinating Centre—Amanda Erratt, Melanie Lacalamita.; Cunningham, Evan; Hajarizadeh, Behzad; Grebely, Jason; Dore, Gregory; Marks, Pip; Shaw, Ineke; Siriragavan, Sharmila; Amin, Janaki; Quiene, Sophie; Petoumenos, Kathy; Bruggmann, Philip; Schmid, Patrick; Castro, Erika; Moriggia, Alberto; Lacombe, Karine; Daulouede, Jean-Pierre; Dalgard, Olav; Conway, Brian; Fraser, Christopher; Powis, Jeff; Feld, Jordan; Bruneau, Julie; Cooper, Curtis; Gane, Ed; Stedman, Catherine; Matthews, Gail; Dunlop, Adrian; Hellard, Margaret; Kronborg, Ian; Shaw, David; Litwin, Alain; Norton, Brianna; Thurnheer, Maria Christine; Weltman, Martin; Read, Philip; Dillon, John; Kessler, Simone; Knapp, Cornelia; Oprandi, Lorenza; Messina, Paola; Pantic, Marzia; Le Cam, Manuela; Maitre, Cecilia; Andreassen, Jessica; Melkeraaen, Ingunn; Tollefsen, Merete Moen; Pagarigan, Hannah; Milne, Rozalyn; Mason, Kate; Kaznowski, Diana; Zou, Lily; Bouchard, Rachel; Kotsoros, Barbara; Muir, Miriam; Milloy, Jessica; Oliver, Victoria; Noonan, Tracy; Sevehon, Alison; Hazelwood, Susan; Hall, Michelle; Hagenauer, Michelle; Liddle, Rachel; Ferguson, Catherine; Agyemang, Linda; Patel, Hiral; Soloway, Irene; Cerocchi, Orlando; Lacalamita, Melanie; Fragomeli, Vincenzo; Gilliver, Rosie; Lothian, Rebecca; Cleary, Shirley; Johnston, Linda; Middleton, Sarah; D’Amico, Ronald; McGovern, Barbara; Anderson, Jonathan; Zhong, Ze; Keane, Fiona; Tatsch, Fernando; Brainard, Diana; McHutchison, John

doi:10.1016/j.jval.2022.12.016

Cited by 4 publications

(1 citation statement)

References 66 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As consistent with previous studies [ 21 , 25 , 26 ], gender was not found statistically significantly associated with HRQoL in our study population. In this analysis, participants who were employed and those who had stable housing reported higher mean and median HRQoL scores.…”

Section: Discussionsupporting

confidence: 92%

Health-related quality of life among people who inject drugs in Australia

et al. 2023

Self Cite

View full text Add to dashboard Cite

Purpose There is limited research on health-related quality of life (HRQoL) among people who inject drugs (PWID). We aimed to evaluate factors associated with HRQoL among a cohort of PWID in Australia. Methods Participants were enrolled in an observational cohort study (the LiveRLife Study) between 2014 and 2018 at 15 sites in Australia. They provided fingerstick whole-blood samples for point-of-care HCV RNA testing and underwent transient elastography to assess liver disease. Participants completed the EQ-5D-3L survey at enrolment. Regression models were used to assess the impact of clinical and socioeconomic characteristics on the EQ-5D-3L scores. Results Among 751 participants (median age, 43 years; 67% male), 63% reported injection drug use in the past month, 43% had current HCV infection, and 68% had no/mild liver fibrosis (F0/F1). The mean EQ-5D-3L and EQ-VAS scores were 0.67 and 62, respectively, for the overall study population. There was no significant difference in the EQ-5D-3L scores among people with and without recent injecting drug use (mean: 0.66 vs. 0.68, median: 0.73 vs. 0.78, P = 0.405), and among people receiving and not receiving opioid agonist therapy (mean: 0.66 vs. 0.68, median: 0.73 vs. 0.76, P = 0.215). Participants who were employed were found to have the highest mean EQ-5D-3L (0.83) and EQ-VAS scores (77). The presence of current HCV infection, liver fibrosis stage, and high-risk alcohol consumption had little impact on HRQoL. Conclusions The study findings provide important HRQoL data for economic evaluations, useful for guiding the allocation of resources for HCV elimination strategies and interventions among PWID.

show abstract

Section: Discussionsupporting

confidence: 92%

Health-related quality of life among people who inject drugs in Australia

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Health-Related Quality of Life of People Who Inject Drugs: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage Study

Cheng,

Valerio,

Cunningham

et al. 2024

Value in Health

View full text Add to dashboard Cite

Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination

Shih,

Stone,

Martin

et al. 2023

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Background The Surveillance and Treatment of Prisoners with hepatitis C (SToP-C) study demonstrated that scaling-up of direct-acting antiviral (DAA) treatment reduced hepatitis C virus (HCV) transmission. We evaluated the cost-effectiveness of scaling-up HCV treatment in state-wide prison services incorporating long-term outcomes across custodial and community settings. Methods A dynamic model of incarceration and HCV transmission amongst people who inject drugs (PWID) in New South Wales, Australia, was extended to include former PWID and long-term HCV progression. Using Australian costing data, we estimated the cost-effectiveness of scaling-up HCV treatment in prisons by 44% (as achieved by the SToP-C study) for 10 years (2021-2030) before reducing to baseline levels, compared to a status-quo scenario. The mean incremental cost-effectiveness ratio (ICER) was estimated by comparing the differences in costs and quality-adjusted life-years (QALYs) between the scale-up and status-quo scenarios over 40 years (2021 to 2060) discounted at 5% per annum. Univariate and probabilistic sensitivity analyses were performed. Results Scaling-up HCV treatment in the state-wide prison service is projected to be cost-effective with a mean ICER of A$12,968/QALY gained. The base-case scenario gains 275 QALYs over 40 years at a net incremental cost A$3.6 million. Excluding DAA pharmaceutical costs, the mean ICER is reduced to A$6,054/QALY. At the willingness-to-pay threshold of A$50,000/QALY, 100% of simulations are cost-effective at various discount rates, time horizons, and changes of treatment levels in prison and community. Conclusion Scaling-up HCV testing and treatment in prisons is highly cost-effective and should be considered a priority in the national elimination strategy.

show abstract

Patient-Reported Outcomes During and After Hepatitis C Virus Direct-Acting Antiviral Treatment Among People Who Inject Drugs

Cited by 4 publications

References 66 publications

Health-related quality of life among people who inject drugs in Australia

Health-related quality of life among people who inject drugs in Australia

Health-Related Quality of Life of People Who Inject Drugs: The Enhancing Treatment of Hepatitis C in Opioid Substitution Settings Engage Study

Scale-up of Direct-Acting Antiviral Treatment in Prisons Is Both Cost-effective and Key to Hepatitis C Virus Elimination

Contact Info

Product

Resources

About